As of May 27, 2025, Clovis Oncology Inc (CLVS) reports a EV/EBITDA of -3.06.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Clovis Oncology Inc's EV/EBITDA to Peers
To better understand Clovis Oncology Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Clovis Oncology Inc (CLVS) | -3.06 |
| Abbvie Inc (ABBV) | 17.74 |
| Regeneron Pharmaceuticals Inc (REGN) | 14.51 |
| Amgen Inc (AMGN) | 14.47 |
| CytomX Therapeutics Inc (CTMX) | 10.54 |
| Gilead Sciences Inc (GILD) | 9.26 |
Compared to its competitors, Clovis Oncology Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.